David Denton

Background: In recent history Metabolic-Associated Steatotic Liver Disease (MASLD) has emerged as a major global health challenge, closely tied to dietary patterns and metabolic dysregulation¹. Recent research highlights the distinct metabolic and molecular consequences of fructose consumption, as opposed to glucose, in promoting hepatic steatosis and systemic metabolic dysfunction. Fructose’s unique metabolic pathway in the liver, its propensity to upregulate lipogenic and purine synthesis genes, and its impact on uric acid production collectively distinguish it as a potent dietary driver of MASLD³. Despite growing awareness, gaps remain regarding the precise molecular mediators linking fructose intake to MASLD progression and the potential for targeted interventions, especially in pediatric populations and those with comorbid hyperuricemia.

Objective: This literature review aims to synthesize recent findings on the molecular mechanisms by which fructose consumption promotes MASLD, focusing on the roles of SREBP1c, PPAT, and mTOR signaling in hepatic lipid and uric acid metabolism, and to explore emerging evidence for immune gene regulation as a determinant of disease progression and therapeutic targeting.

Methods: A comprehensive literature search was conducted using PubMed and other biomedical databases, using keywords such as “fructose metabolism,” “MASLD,” “SREBP1c,” “mTOR,” “uric acid,” and “immune gene expression.” Key studies included animal models of high-fat and high-fructose diets, transcriptomic analyses of liver tissue, randomized controlled trials of dietary interventions in children, and mechanistic investigations in hepatocyte cultures and genetically modified mice.

Results: Fructose, unlike glucose, strongly upregulates hepatic SREBP1c and Khk, driving de novo lipogenesis and triglyceride accumulation^3,6. It simultaneously impairs insulin signaling and promotes hepatomegaly and glucose intolerance. Mechanistically, fructose’s rapid depletion of intracellular ATP and subsequent activation of fructokinase C initiates a cascade of metabolic disturbances, including increased oxidative stress and uric acid production³. Notably, fructose stimulates purine de novo synthesis via mTOR⁹ activation, elevating expression of PPAT⁹ and xanthine oxidase, thereby exacerbating hyperuricemia. Experimental models demonstrate that uric acid is not merely a biomarker but an active driver of hepatic steatosis, acting through ROS/JNK/AP-1 signaling to enhance lipogenic gene expression and disrupt mitochondrial function⁸. Therapeutic interventions targeting uric acid metabolism, such as xanthine oxidase inhibition, attenuate hepatic lipid accumulation in hyperuricemic models. In pediatric obesity, short-term fructose restriction significantly reduces liver fat and improves insulin kinetics, underscoring the rapid and reversible impact of dietary modification. Additionally, transcriptomic profiling identifies immune-related genes (JUN, CCL20) as stage-specific regulators of MASLD progression, offering novel biomarkers for non-invasive diagnosis and targets for personalized immunomodulatory therapy⁴.

Conclusions: Fructose’s distinct metabolic and molecular effects spanning enhanced lipogenesis, purine synthesis, uric acid elevation, and immune modulation position it as a central factor in MASLD pathogenesis. The evidence supports dietary fructose restriction as a practical, non-pharmacologic intervention, particularly in children, and highlights the therapeutic promise of targeting mTOR, PPAT, and uric acid pathways^3,6,9. The identification of immune gene signatures further enables precision medicine approaches, facilitating stage-specific interventions and improved disease monitoring. Future research should focus on translating these mechanistic insights into tailored therapies and public health strategies to curb the growing MASLD epidemic.

Work Cited:

1. Murag S, Ahmed A, Kim D. Recent Epidemiology of Nonalcoholic Fatty Liver Disease. Gut and Liver. Published online September 15, 2020. doi:https://doi.org/10.5009/gnl20127
2. Yu S, Li C, Ji G, Zhang L. The Contribution of Dietary Fructose to Non-alcoholic Fatty Liver Disease. Frontiers in Pharmacology. 2021;12. doi:https://doi.org/10.3389/fphar.2021.783393
3. Dholariya SJ, Orrick JA. Biochemistry, Fructose Metabolism. PubMed. Published October 17, 2022. https://www.ncbi.nlm.nih.gov/books/NBK576428/
4. He R, Guan C, Zhao X, Yu L, Cui Y. Expression of immune related genes and possible regulatory mechanisms in different stages of non-alcoholic fatty liver disease. Frontiers in Immunology. 2024;15. doi:https://doi.org/10.3389/fimmu.2024.1364442
5. Schwarz JM, Noworolski SM, Erkin-Cakmak A, et al. Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children With Obesity. Gastroenterology. 2017;153(3):743-752. doi:https://doi.org/10.1053/j.gastro.2017.05.043
6. Softic S, Gupta MK, Wang GX, et al. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. Journal of Clinical Investigation. 2017;127(11):4059-4074. doi:https://doi.org/10.1172/jci94585
7. Hoang SA, Oseini A, Feaver RE, et al. Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease. Scientific Reports. 2019;9(1). doi:https://doi.org/10.1038/s41598-019-48746-5
8. Xie D, Zhao H, Lu J, et al. High uric acid induces liver fat accumulation via ROS/JNK/AP-1 signaling. Endocrinology and metabolism/American journal of physiology: endocrinology and metabolism. 2021;320(6):E1032-E1043. doi:https://doi.org/10.1152/ajpendo.00518.2020
9. Zhang P, Sun H, Cheng X, et al. Dietary intake of fructose increases purine de novo synthesis: A crucial mechanism for hyperuricemia. Frontiers in Nutrition. 2022;9. doi:https://doi.org/10.3389/fnut.2022.1045805